You are here

Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms

Last updated on November 11, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Brno, , 612 00 Czech Republic
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Prostatic Hyperplasia
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male subjects, aged 40 years and above, with documented LUTS with an International
Prostate Symptom Score (IPSS) ≥13.

- Clinical diagnosis of BPH

- Qmax 5 to 15 ml/sec with a voided volume of ≥150 ml

- Urodynamically defined bladder outlet obstruction

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- prostate cancer

- Post-void residual urine volume >200 ml

- Documented UTI

- History of relevant urological surgery

NCT00408954
Pfizer
Completed
Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
Official Title  ICMJE A Multi Center Randomized Cross Over Double Blind Third Party Open Placebo Controlled Pilot Study to Assess the Urodynamic Effects of Modified Release UK-369,003 in Men With Lower Urinary Tract Symptoms.
Brief SummaryThis is a pilot study to generate hypotheses about the urodynamic effects of UK-369,003 in men with lower urinary tract symptoms.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Prostatic Hyperplasia
Intervention  ICMJE
  • Drug: UK-369,003
    100 mg MR tablet once daily for 2 weeks
  • Drug: UK-369,003
    UK-369,003-100 mg MR formulation for 2 weeks
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Intervention: Drug: UK-369,003
  • Active Comparator: UK-369,003
    Intervention: Drug: UK-369,003
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 22, 2008)
27
Original Enrollment  ICMJE
 (submitted: December 7, 2006)
20
Actual Study Completion Date  ICMJE June 2008
Actual Primary Completion DateJune 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male subjects, aged 40 years and above, with documented LUTS with an International Prostate Symptom Score (IPSS) ?13.
  • Clinical diagnosis of BPH
  • Qmax 5 to 15 ml/sec with a voided volume of ?150 ml
  • Urodynamically defined bladder outlet obstruction

Exclusion Criteria:

  • prostate cancer
  • Post-void residual urine volume >200 ml
  • Documented UTI
  • History of relevant urological surgery
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 40 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Czech Republic,   Netherlands,   Slovakia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00408954
Other Study ID Numbers  ICMJE A3711045
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyDirector, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateNovember 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now